Support for the involvement of the KCNK2 gene in major depressive disorder and response to antidepressant treatment

Pharmacogenetics and Genomics

Volumn 19, Issue 10, 2009, Pages 735-741

  Liou, Ying Jay ^a,b,d   Chen, Tai Jui ^e   Tsai, Shih Jen ^b,d   Yu, Younger W Y ^f   Cheng, Chih Ya ^a   Hong, Chen Jee ^b,c,d  

^a Institute of Clinical Medicine   (China)

^b Fu Jen Catholic Uiversity   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e I SHOU UNIVERSITY   (Taiwan)

^f Yu's Psychiatric Clinic   (Taiwan)

Author keywords

Antidepressant; KCNK2; Major depressive disorder; Pharmacogenetics; TREK 1

Indexed keywords

ALPRAZOLAM; CITALOPRAM; CLONAZEPAM; FLUOXETINE; LORAZEPAM; POTASSIUM CHANNEL; POTASSIUM CHANNEL KCNK2; UNCLASSIFIED DRUG;

ADULT; ANOREXIA; ANXIETY; ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; EPIGASTRIC PAIN; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAND TREMOR; HEADACHE; HEART PALPITATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INCREASED APPETITE; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; PRIORITY JOURNAL; REMISSION; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SWEATING; TREATMENT DURATION; TREATMENT RESPONSE; XEROSTOMIA;

ADULT; AGED; ALLELES; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POTASSIUM CHANNELS, TANDEM PORE DOMAIN; PSYCHIATRIC STATUS RATING SCALES;

ANIMALIA;

EID: 70349575487     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32832cbe61     Document Type: Article

References (20)

1. Lecrubier Y. The burden of depression and anxiety in general medicine. J Clin Psychiatry 2001; 62 (Suppl 8):4-9.
2. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 2000; 157:1552-1562.
3. Foley DL, Neale MC, Kendler KS. Reliability of a lifetime history of major depression: implications for heritability and co-morbidity. Psychol Med 1998; 28:857-870.
4. Levinson DF. The genetics of depression: a review. Biol Psychiatry 2006; 60:84-92.
5. Donner J, Pirkola S, Silander K, Kananen L, Terwilliger JD, Lonnqvist J, et al. An association analysis of murine anxiety genes in humans implicates novel candidate genes for anxiety disorders. Biol Psychiatry 2008; 64:672-680.
6. Gordon JA, Hen R. TREKing toward new antidepressants. Nat Neurosci 2006; 9:1081-1083.
7. Heurteaux C, Lucas G, Guy N, El YM, Thummler S, Peng XD, et al. Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype. Nat Neurosci 2006; 9:1134-1141.
8. Honore E. The neuronal background K2P channels: focus on TREK1. Nat Rev Neurosci 2007; 8:251-261.
9. Deng PY, Poudel SK, Rojanathammanee L, Porter JE, Lei S. Serotonin inhibits neuronal excitability by activating two-pore domain K+ channels in the entorhinal cortex. Mol Pharmacol 2007; 72:208-218.
10. Kennard LE, Chumbley JR, Ranatunga KM, Armstrong SJ, Veale EL, Mathie A. Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine. Br J Pharmacol 2005; 144:821-829.
11. Florez JC, Sjogren M, Burtt N, Orho-Melander M, Schayer S, Sun M, et al. Association testing in 9000 people fails to confirm the association of the insulin receptor substrate-1 G972R polymorphism with type 2 diabetes. Diabetes 2004; 53:3313-3318.
12. Perlis RH, Moorjani P, Fagerness J, Purcell S, Trivedi MH, Fava M, et al. Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study. Neuropsychopharmacology 2008; 33:2810-2819.
13. Cheng AT, Tien AY, Chang CJ, Brugha TS, Cooper JE, Lee CS, et al. Cross-cultural implementation of a Chinese version of the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) in Taiwan. Br J Psychiatry 2001; 178:567-572.
14. Serretti A, Kato M, Kennedy JL. Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics J 2008; 8:90-100.
15. Gau YT, Liou YJ, Yu YW, Chen TJ, Lin MW, Tsai SJ, et al. Evidence for association between genetic variants of p75 neurotrophin receptor (p75NTR) gene and antidepressant treatment response in Chinese major depressive disorder. Am J Med Genet B Neuropsychiatr Genet 2008; 147B:594-599.
16. Balding DJ. A tutorial on statistical methods for population association studies. Nat Rev Genet 2006; 7:781-791.
17. Nielsen DM, Ehm MG, Weir BS. Detecting marker-disease association by testing for Hardy-Weinberg disequilibrium at a marker locus. Am J Hum Genet 1998; 63:1531-1540.
18. Comings DE, MacMurray JP. Molecular heterosis: a review. Mol Genet Metab 2000; 71:19-31.
19. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet 2001; 29:306-309.
20. Sullivan PF. Spurious genetic associations. Biol Psychiatry 2007; 61:1121-1126.